Source: Eur Respir J, 56 (2) 2000008; 10.1183/13993003.00008-2020
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Manreet K. Kanwar, Mardi Gomberg-Maitland, Marius Hoeper, Christine Pausch, David Pittrow, Geoff Strange, James J. Anderson, Carol Zhao, Jacqueline V. Scott, Marek J. Druzdzel, Jidapa Kraisangka, Lisa Lohmueller, James Antaki, Raymond L. Benza. Risk stratification in pulmonary arterial hypertension using Bayesian analysis. Eur Respir J, 56 (2) 2000008; 10.1183/13993003.00008-2020

Member's Comments

No comment yet.

Related content which might interest you: Risk stratification in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – New trends in the management of pulmonary hypertension Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 390-398 Year: 2016 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017 Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018 Year: 2018 Risk stratification and medical therapy of pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801889; 10.1183/13993003.01889-2018 Year: 2019 Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model Source: Eur Respir J, 50 (2) 1700740; 10.1183/13993003.00740-2017 Year: 2017 A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension Source: Eur Respir J, 56 (3) 2000513; 10.1183/13993003.00513-2020 Year: 2020 Novel biomarkers for risk stratification in pulmonary arterial hypertension Source: ERJ Open Res 2015; 1: 00008-2015 Year: 2015 In-depth risk stratification in pulmonary arterial hypertension Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (6) 1802004; 10.1183/13993003.02004-2018 Year: 2019 Analysis of mortality risk factors in a population with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010 Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension Source: Eur Respir J, 50 (2) 1700889; 10.1183/13993003.00889-2017 Year: 2017 Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model Source: Eur Respir J, 52 (4) 1800497; 10.1183/13993003.00497-2018 Year: 2018 Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 Diagnosis of pulmonary hypertension from MR image based computational models of pulmonary vascular haemodynamics and decision tree analysis Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Prevalence of sarcoidosis-associated pulmonary hypertension: cumulative analysis of two PULSAR studies Source: Eur Respir J, 55 (2) 1902223; 10.1183/13993003.02223-2019 Year: 2020 A new molecular genetic diagnostic approach for pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Validation of two predictive models for survival in pulmonary arterial hypertension Source: Eur Respir J 2015; 46: 152-164 Year: 2015 Risk assessment, therapy and cardiovascular comorbidity in patients with pulmonary arterial hypertension Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020